Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 135-146

  Goyal, Jatinder ^a   Antonarakis, Emmanuel S ^b  

^a University of Alabama at Birmingham   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone metastases; Castration resistant prostate cancer; Radiopharmaceuticals; Radium 223; Samarium 153; Strontium 89

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANALGESIC AGENT; CARBOXY TERMINAL TELOPEPTIDE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; FLUOROURACIL; GEMCITABINE; KETOCONAZOLE; LEXIDRONAM SAMARIUM SM 153; MITOMYCIN C; PLACEBO; PROCOLLAGEN; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; STRONTIUM 89; UNCLASSIFIED DRUG; VINBLASTINE;

ANALGESIA; ANEMIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SHORT SURVEY; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84863093187     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.001     Document Type: Review

References (98)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002, 52:154-179.
3. Connolly R.M., Carducci M.A., Antonarakis E.S. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J. Androl. 2012, 14:177-186.
4. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. J. Am. Med. Assoc. 2005, 294:238-244.
5. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005, 23:8253-8261.
6. Antonarakis E.S., Armstrong A.J. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011, 14:192-205.
7. Antonarakis E.S., Eisenberger M.A. Expanding treatment options for metastatic prostate cancer. New Engl. J. Med. 2011, 364:2055-2058.
8. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 2004, 351:1502-1512.
9. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., Roessner M., Gupta S., Sartor A.O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
10. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 2010, 363:411-422.
11. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Cheng T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Flechon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I. Abiraterone and increased survival in metastatic prostate cancer. New Engl. J. Med. 2011, 364:1995-2005.
12. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol. 2000, 31:578-583.
13. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl. J. Med. 2004, 351:1513-1520.
14. Brown M.L. Bone scintigraphy in benign and malignant tumors. Radiol. Clin. North Am. 1993, 31:731-738.
15. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J. Nucl. Med. 2006, 47:287-297.
16. Tombal B., Lecouvet F. Modern detection of prostate cancer's bone metastasis: is the bone scan era over?. Adv. Urol. 2012, 2012:893193.
17. Sabbatini P., Larson S.M., Kremer A., Zhang Z.F., Sun M., Yeung H., Imbriaco M., Horak I., Conolly M., Ding C., Ouyang P., Kelly W.K., Scher H.I. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J. Clin. Oncol. 1999, 17:948-957.
18. Bilezikian J.P. Osteoporosis in men. J. Clin. Endocrinol. Metab. 1999, 84:3431-3434.
19. Cleeland C.S., Gonin R., Hatfield A.K., Edmonson J.H., Blum R.H., Stewart J.A., Pandya K.J. Pain and its treatment in outpatients with metastatic cancer. New Engl. J. Med. 1994, 330:592-596.
20. Newling D.W., Denis L., Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer 1993, 72:3793-3798.
21. Muir G.H., Butta A., Shearer R.J., Fisher C., Dearnaley D.P., Flanders K.C., Sporn M.B., Colletta A.A. Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br. J. Cancer 1994, 69:130-134.
22. Rajan R., Vanderslice R., Kapur S., Lynch J., Thompson R., Djakiew D. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 1996, 28:1-9.
23. Saarto T., Janes R., Tenhunen M., Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur. J. Pain 2002, 6:323-330.
24. Roodman G.D. Mechanisms of bone metastasis. New Engl. J. Med. 2004, 350:1655-1664.
25. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88:2919-2926.
26. Cook R.J., Coleman R., Brown J., Lipton A., Major P., Hei Y.J., Saad F., Smith M.R. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 2006, 12:3361-3367.
27. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat. Med. 2004, 18:267-274.
28. Paes F.M., Serafini A.N. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin. Nucl. Med. 2010, 40:89-104.
29. Jadad A.R., Browman G.P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. J. Am. Med. Assoc. 1995, 274:1870-1873.
30. Christo P.J., Mazloomdoost D. Cancer pain and analgesia. Ann. NY Acad. Sci. 2008, 1138:278-298.
31. Tong D., Gillick L., Hendrickson F.R. The palliation of symptomatic osseous metastases: final results of the study by the radiation therapy oncology group. Cancer 1982, 50:893-899.
32. Lin A., Ray M.E. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev. 2006, 25:669-675.
33. Bourgeois D.J., Kraus S., Maaloof B.N., Sartor O. Radiation for bone metastases. Curr. Opin. Support Palliat. Care 2011, 5:227-232.
34. Saylor P.J., Lee R.J., Smith M.R. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J. Clin. Oncol. 2011, 29:3705-3714.
35. Morris M.J., Scher H.I. Clinical approaches to osseous metastases in prostate cancer. Oncologist 2003, 8:161-173.
36. Robinson R.G. Strontium-89 - precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993, 72:3433-3435.
37. Taylor A.J. Strontium-89 for the palliation of bone pain due to metastatic disease. J. Nucl. Med. 1994, 35:2054.
38. Turner J.H., Claringbold P.G., Hetherington E.L., Sorby P., Martindale A.A. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J. Clin. Oncol. 1989, 7:1926-1931.
39. Maxon H.R., Deutsch E.A., Thomas S.R., Libson K., Lukes S.J., Williams C.C., Ali S. Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988, 166:501-507.
40. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 1987, 28:495-504.
41. Farhanghi M., Holmes R.A., Volkert W.A., Logan K.W., Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med. 1992, 33:1451-1458.
42. De Klerk J.M., Zonnenberg B.A., Blijham G.H., Van Het Schip A.D., Hoekstra A., Han S.H., Quirijnen J.M., Van Dijk A., Van Rijk P.P. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res. 1997, 17:1773-1777.
43. Bruland O.S., Nilsson S., Fisher D.R., Larsen R.H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin. Cancer Res. 2006, 12:6250s-6257s.
44. Bodei L., Lam M., Chiesa C., Flux G., Brans B., Chiti A., Giammarile F. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1934-1940.
45. Chow E., Zeng L., Salvo N., Dennis K., Tsao M., Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin. Oncol. (R. Coll. Radiol.) 2012, 24:112-124.
46. Finlay I.G., Mason M.D., Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005, 6:392-400.
47. Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev. Urol. 2004, 6(Suppl 10):S3-S12.
48. Turner S.L., Gruenewald S., Spry N., Gebski V. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br. J. Cancer 2001, 84:297-302.
49. Lewington V.J. Bone-seeking radionuclides for therapy. J. Nucl. Med. 2005, 46:38S-47S.
50. Robinson R.G., Blake G.M., Preston D.F., McEwan A.J., Spicer J.A., Martin N.L., Wegst A.V., Ackery D.M. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989, 9:271-281.
51. Blake G.M., Zivanovic M.A., McEwan A.J., Ackery D.M. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur. J. Nucl. Med. 1986, 12:447-454.
52. Silberstein E.B., Williams C. Strontium-89 therapy for the pain of osseous metastases. J. Nucl. Med. 1985, 26:345-348.
53. Laing A.H., Ackery D.M., Bayly R.J., Buchanan R.B., Lewington V.J., McEwan A.J., Macleod P.M., Zivanovic M.A. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br. J. Radiol. 1991, 64:816-822.
54. Mertens W.C., Stitt L., Porter A.T. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?. Am. J. Clin. Oncol. 1993, 16:238-242.
55. Lewington V.J., McEwan A.J., Ackery D.M., Bayly R.J., Keeling D.H., Macleod P.M., Porter A.T., Zivanovic M.A. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer 1991, 27:954-958.
56. Buchali K., Correns H.J., Schuerer M., Schnorr D., Lips H., Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur. J. Nucl. Med. 1988, 14:349-351.
57. Robinson R.G., Preston D.F., Schiefelbein M., Baxter K.G. Strontium 89 therapy for the palliation of pain due to osseous metastases. J. Am. Med. Assoc. 1995, 274:420-424.
58. Kraeber-Bodere F., Campion L., Rousseau C., Bourdin S., Chatal J.F., Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur. J. Nucl. Med. 2000, 27:1487-1493.
59. Kasalicky J., Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur. J. Nucl. Med. 1998, 25:1362-1367.
60. Dafermou A., Colamussi P., Giganti M., Cittanti C., Bestagno M., Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med. 2001, 28:788-798.
61. Porter A.T., McEwan A.J., Powe J.E., Reid R., McGowan D.G., Lukka H., Sathyanarayana J.R., Yakemchuk V.N., Thomas G.M., Erlich L.E., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25:805-813.
62. Smeland S., Erikstein B., Aas M., Skovlund E., Hess S.L., Fossa S.D. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:1397-1404.
63. Oosterhof G.O., Roberts J.T., de Reijke T.M., Engelholm S.A., Horenblas S., von der Maase H., Neymark N., Debois M., Collette L. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol. 2003, 44:519-526.
64. Quilty P.M., Kirk D., Bolger J.J., Dearnaley D.P., Lewington V.J., Mason M.D., Reed N.S., Russell J.M., Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. 1994, 31:33-40.
65. Amato R.J., Hernandez-McClain J., Henary H. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am. J. Clin. Oncol. 2008, 31:532-538.
66. Pagliaro L.C., Delpassand E.S., Williams D., Millikan R.E., Tu S.M., Logothetis C.J. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003, 97:2988-2994.
67. Sciuto R., Festa A., Rea S., Pasqualoni R., Bergomi S., Petrilli G., Maini C.L. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J. Nucl. Med. 2002, 43:79-86.
68. Nilsson S., Strang P., Ginman C., Zimmermann R., Edgren M., Nordstrom B., Ryberg M., Kalkner K.M., Westlin J.E. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J. Pain Symptom Manage 2005, 29:352-357.
69. Tu S.M., Millikan R.E., Mengistu B., Delpassand E.S., Amato R.J., Pagliaro L.C., Daliani D., Papandreou C.N., Smith T.L., Kim J., Podoloff D.A., Logothetis C.J. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001, 357:336-341.
70. Eary J.F., Collins C., Stabin M., Vernon C., Petersdorf S., Baker M., Hartnett S., Ferency S., Addison S.J., Appelbaum F., et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. 1993, 34:1031-1036.
71. Singh A., Holmes R.A., Farhangi M., Volkert W.A., Williams A., Stringham L.M., Ketring A.R. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J. Nucl. Med. 1989, 30:1814-1818.
72. Resche I., Chatal J.F., Pecking A., Ell P., Duchesne G., Rubens R., Fogelman I., Houston S., Fauser A., Fischer M., Wilkins D. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer. 1997, 33:1583-1591.
73. Valicenti R.K., Trabulsi E., Intenzo C., Lavarino J., Xu Y., Chervoneva I. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79:732-737.
74. Sandeman T.F., Budd R.S., Martin J.J. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin. Oncol. (R. Coll. Radiol.) 1992, 4:160-164.
75. Collins C., Eary J.F., Donaldson G., Vernon C., Bush N.E., Petersdorf S., Livingston R.B., Gordon E.E., Chapman C.R., Appelbaum F.R. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J. Nucl. Med. 1993, 34:1839-1844.
76. Dolezal J., Vizda J., Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol. Int. 2007, 78:50-57.
77. Serafini A.N., Houston S.J., Resche I., Quick D.P., Grund F.M., Ell P.J., Bertrand A., Ahmann F.R., Orihuela E., Reid R.H., Lerski R.A., Collier B.D., McKillop J.H., Purnell G.L., Pecking A.P., Thomas F.D., Harrison K.A. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 1998, 16:1574-1581.
78. Sartor O., Reid R.H., Hoskin P.J., Quick D.P., Ell P.J., Coleman R.E., Kotler J.A., Freeman L.M., Olivier P. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
79. Morris M.J., Pandit-Taskar N., Carrasquillo J., Divgi C.R., Slovin S., Kelly W.K., Rathkopf D., Gignac G.A., Solit D., Schwartz L., Stephenson R.D., Hong C., Delacruz A., Curley T., Heller G., Jia X., O'Donoghue J., Larson S., Scher H.I. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol. 2009, 27:2436-2442.
80. Fizazi K., Beuzeboc P., Lumbroso J., Haddad V., Massard C., Gross-Goupil M., Di Palma M., Escudier B., Theodore C., Loriot Y., Tournay E., Bouzy J., Laplanche A. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27:2429-2435.
81. Tennvall J., Abrahamsson P.A., Ahlgren G., Darte L., Flodgren P., Garkavij M., Strand S.E. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma. Scand. J. Urol. Nephrol. 2000, 34:188-193.
82. Kolesnikov-Gauthier H., Carpentier P., Depreux P., Vennin P., Caty A., Sulman C. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J. Nucl. Med. 2000, 41:1689-1694.
83. Maxon H.R., Schroder L.E., Thomas S.R., Hertzberg V.S., Deutsch E.A., Scher H.I., Samaratunga R.C., Libson K.F., Williams C.C., Moulton J.S., et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990, 176:155-159.
84. Sciuto R., Tofani A., Festa A., Giannarelli D., Pasqualoni R., Maini C.L. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J. Nucl. Med. 2000, 41:647-654.
85. Han S.H., de Klerk J.M., Tan S., van het Schip A.D., Derksen B.H., van Dijk A., Kruitwagen C.L., Blijham G.H., van Rijk P.P., Zonnenberg B.A. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo controlled rhenium study. J. Nucl. Med. 2002, 43:1150-1156.
86. Maxon H.R., Schroder L.E., Hertzberg V.S., Thomas S.R., Englaro E.E., Samaratunga R., Smith H., Moulton J.S., Williams C.C., Ehrhardt G.J., et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J. Nucl. Med. 1991, 32:1877-1881.
87. Liepe K., Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl. Med. Commun. 2007, 28:623-630.
88. Liepe K., Runge R., Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J. Cancer Res. Clin. Oncol. 2005, 131:60-66.
89. Baczyk M., Czepczynski R., Milecki P., Pisarek M., Oleksa R., Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl. Med. Commun. 2007, 28:245-250.
90. Nilsson S., Larsen R.H., Fossa S.D., Balteskard L., Borch K.W., Westlin J.E., Salberg G., Bruland O.S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 2005, 11:4451-4459.
91. Ritter M.A., Cleaver J.E., Tobias C.A. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977, 266:653-655.
92. Larsen R.H., Murud K.M., Akabani G., Hoff P., Bruland O.S., Zalutsky M.R. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J. Nucl. Med. 1999, 40:1197-1203.
93. Henriksen G., Fisher D.R., Roeske J.C., Bruland O.S., Larsen R.H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J. Nucl. Med. 2003, 44:252-259.
94. Henriksen G., Breistol K., Bruland O.S., Fodstad O., Larsen R.H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002, 62:3120-3125.
95. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., de Haes J.C., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85:365-376.
96. Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., Lennernas B., Petersson U., Johannessen D.C., Sokal M., Pigott K., Yachnin J., Garkavij M., Strang P., Harmenberg J., Bolstad B., Bruland O.S. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007, 8:587-594.
97. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., Figg W.D., Freidlin B., Halabi S., Hudes G., Hussain M., Kaplan R., Myers C., Oh W., Petrylak D.P., Reed E., Roth B., Sartor O., Scher H., Simons J., Sinibaldi V., Small E.J., Smith M.R., Trump D.L., Wilding G., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J. Clin. Oncol. 1999, 17:3461-3467.
98. Parker C., Heinrich D., O'Sullivan J.M., Fossa S., Chodacki A., Demkow T., Cross A., Bolstad B., Garcia-Vargas J., Sartor O. Overall survival benefit of radium-223 chloride in the treatment of patients with symptomatic bone metastases in castration resistant prostate cancer: a phase III randomized trial (ALSYMPCA). J. Clin. Oncol. 2012, 30. (abstract 8).